Dr. Lal PathLabs’ arm to acquire 'Satya Pathology and Diagnostic Centre'

13 Dec 2017 Evaluate

Dr. Lal PathLabs’ subsidiary -- Paliwal Diagnostics has received an approval to acquire a Proprietorship Concern. i.e. Satya Pathology and Diagnostic Centre (SPDC).  The Board of Directors of the company's Subsidiary at their meeting held on December 12, 2017, approved the same.

The company's subsidiary has decided to acquire 100% stake in SPDC with the objective of strengthening its presence in market.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal Pathlabs Share Price

2387.05 56.05 (2.40%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Aster DM Healthcare 359.00
Apollo Hospital Ent. 6260.00
Max Healthcare Inst 802.00
Narayana Hrudayalay 1280.00
Global Health 1438.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.